The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global PD-1 Antibody Drug Market Research Report 2024

Global PD-1 Antibody Drug Market Research Report 2024

Publishing Date : Aug, 2023

License Type :
 

Report Code : 1765621

No of Pages : 105

Ask Your Query

Synopsis
PD-1 is an immune checkpoint inhibitor, which is relatively widely used clinically

Global PD-1 Antibody Drug market is projected to reach US$ 84110 million in 2029, increasing from US$ 33000 million in 2022, with the CAGR of 14.3% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole PD-1 Antibody Drug market research.

Key manufacturers engaged in the PD-1 Antibody Drug industry include Novartis, Thermo Fisher, InvivoGen, BioVision Inc., Abcam, Bristol-Myers Squibb, Merck, Ono Pharmaceutical Co., Ltd and Eli Lilly, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.

When refers to consumption region, % volume of PD-1 Antibody Drug were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole PD-1 Antibody Drug market and estimated to attract more attentions from industry insiders and investors.

Report Scope

This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global PD-1 Antibody Drug market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.

By Company

  • Novartis
  • Thermo Fisher
  • InvivoGen
  • BioVision Inc.
  • Abcam
  • Bristol-Myers Squibb
  • Merck
  • Ono Pharmaceutical Co., Ltd
  • Eli Lilly
  • Chugai Pharmaceutical Co., Ltd
  • BeiGene
  • AbbVie
  • TG Therapeutics, Inc
  • Beijing Yiqiao Shenzhou Technology Co., Ltd.
  • 3SBio

Segment by Type

  • Pembrolizumab
  • Nivolumab
  • Sindilimab
  • Toripalimab
  • Other

Segment by Application

  • Hospital
  • Clinic
  • Other

Consumption by Region

  • North America (United States, Canada)
  • Europe (Germany, France, U.K., Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, India, Australia, China Taiwan, Indonesia, Thailand, Malaysia)
  • Latin America (Mexico, Brazil, Argentina)
  • Middle East & Africa (Turkey, Saudi Arabia, UAE)

The PD-1 Antibody Drug report covers below items:

Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source

Index

1 PD-1 Antibody Drug Market Overview
1.1 Product Overview and Scope of PD-1 Antibody Drug
1.2 PD-1 Antibody Drug Segment by Type
1.2.1 Global PD-1 Antibody Drug Market Value Comparison by Type (2023-2029)
1.2.2 Pembrolizumab
1.2.3 Nivolumab
1.2.4 Sindilimab
1.2.5 Toripalimab
1.2.6 Other
1.3 PD-1 Antibody Drug Segment by Application
1.3.1 Global PD-1 Antibody Drug Market Value by Application: (2023-2029)
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Other
1.4 Global PD-1 Antibody Drug Market Size Estimates and Forecasts
1.4.1 Global PD-1 Antibody Drug Revenue 2018-2029
1.4.2 Global PD-1 Antibody Drug Sales 2018-2029
1.4.3 Global PD-1 Antibody Drug Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 PD-1 Antibody Drug Market Competition by Manufacturers
2.1 Global PD-1 Antibody Drug Sales Market Share by Manufacturers (2018-2023)
2.2 Global PD-1 Antibody Drug Revenue Market Share by Manufacturers (2018-2023)
2.3 Global PD-1 Antibody Drug Average Price by Manufacturers (2018-2023)
2.4 Global PD-1 Antibody Drug Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of PD-1 Antibody Drug, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of PD-1 Antibody Drug, Product Type & Application
2.7 PD-1 Antibody Drug Market Competitive Situation and Trends
2.7.1 PD-1 Antibody Drug Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest PD-1 Antibody Drug Players Market Share by Revenue
2.7.3 Global PD-1 Antibody Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 PD-1 Antibody Drug Retrospective Market Scenario by Region
3.1 Global PD-1 Antibody Drug Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global PD-1 Antibody Drug Global PD-1 Antibody Drug Sales by Region: 2018-2029
3.2.1 Global PD-1 Antibody Drug Sales by Region: 2018-2023
3.2.2 Global PD-1 Antibody Drug Sales by Region: 2024-2029
3.3 Global PD-1 Antibody Drug Global PD-1 Antibody Drug Revenue by Region: 2018-2029
3.3.1 Global PD-1 Antibody Drug Revenue by Region: 2018-2023
3.3.2 Global PD-1 Antibody Drug Revenue by Region: 2024-2029
3.4 North America PD-1 Antibody Drug Market Facts & Figures by Country
3.4.1 North America PD-1 Antibody Drug Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America PD-1 Antibody Drug Sales by Country (2018-2029)
3.4.3 North America PD-1 Antibody Drug Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe PD-1 Antibody Drug Market Facts & Figures by Country
3.5.1 Europe PD-1 Antibody Drug Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe PD-1 Antibody Drug Sales by Country (2018-2029)
3.5.3 Europe PD-1 Antibody Drug Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific PD-1 Antibody Drug Market Facts & Figures by Country
3.6.1 Asia Pacific PD-1 Antibody Drug Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific PD-1 Antibody Drug Sales by Country (2018-2029)
3.6.3 Asia Pacific PD-1 Antibody Drug Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America PD-1 Antibody Drug Market Facts & Figures by Country
3.7.1 Latin America PD-1 Antibody Drug Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America PD-1 Antibody Drug Sales by Country (2018-2029)
3.7.3 Latin America PD-1 Antibody Drug Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa PD-1 Antibody Drug Market Facts & Figures by Country
3.8.1 Middle East and Africa PD-1 Antibody Drug Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa PD-1 Antibody Drug Sales by Country (2018-2029)
3.8.3 Middle East and Africa PD-1 Antibody Drug Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global PD-1 Antibody Drug Sales by Type (2018-2029)
4.1.1 Global PD-1 Antibody Drug Sales by Type (2018-2023)
4.1.2 Global PD-1 Antibody Drug Sales by Type (2024-2029)
4.1.3 Global PD-1 Antibody Drug Sales Market Share by Type (2018-2029)
4.2 Global PD-1 Antibody Drug Revenue by Type (2018-2029)
4.2.1 Global PD-1 Antibody Drug Revenue by Type (2018-2023)
4.2.2 Global PD-1 Antibody Drug Revenue by Type (2024-2029)
4.2.3 Global PD-1 Antibody Drug Revenue Market Share by Type (2018-2029)
4.3 Global PD-1 Antibody Drug Price by Type (2018-2029)
5 Segment by Application
5.1 Global PD-1 Antibody Drug Sales by Application (2018-2029)
5.1.1 Global PD-1 Antibody Drug Sales by Application (2018-2023)
5.1.2 Global PD-1 Antibody Drug Sales by Application (2024-2029)
5.1.3 Global PD-1 Antibody Drug Sales Market Share by Application (2018-2029)
5.2 Global PD-1 Antibody Drug Revenue by Application (2018-2029)
5.2.1 Global PD-1 Antibody Drug Revenue by Application (2018-2023)
5.2.2 Global PD-1 Antibody Drug Revenue by Application (2024-2029)
5.2.3 Global PD-1 Antibody Drug Revenue Market Share by Application (2018-2029)
5.3 Global PD-1 Antibody Drug Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Novartis
6.1.1 Novartis Corporation Information
6.1.2 Novartis Description and Business Overview
6.1.3 Novartis PD-1 Antibody Drug Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Novartis PD-1 Antibody Drug Product Portfolio
6.1.5 Novartis Recent Developments/Updates
6.2 Thermo Fisher
6.2.1 Thermo Fisher Corporation Information
6.2.2 Thermo Fisher Description and Business Overview
6.2.3 Thermo Fisher PD-1 Antibody Drug Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Thermo Fisher PD-1 Antibody Drug Product Portfolio
6.2.5 Thermo Fisher Recent Developments/Updates
6.3 InvivoGen
6.3.1 InvivoGen Corporation Information
6.3.2 InvivoGen Description and Business Overview
6.3.3 InvivoGen PD-1 Antibody Drug Sales, Revenue and Gross Margin (2018-2023)
6.3.4 InvivoGen PD-1 Antibody Drug Product Portfolio
6.3.5 InvivoGen Recent Developments/Updates
6.4 BioVision Inc.
6.4.1 BioVision Inc. Corporation Information
6.4.2 BioVision Inc. Description and Business Overview
6.4.3 BioVision Inc. PD-1 Antibody Drug Sales, Revenue and Gross Margin (2018-2023)
6.4.4 BioVision Inc. PD-1 Antibody Drug Product Portfolio
6.4.5 BioVision Inc. Recent Developments/Updates
6.5 Abcam
6.5.1 Abcam Corporation Information
6.5.2 Abcam Description and Business Overview
6.5.3 Abcam PD-1 Antibody Drug Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Abcam PD-1 Antibody Drug Product Portfolio
6.5.5 Abcam Recent Developments/Updates
6.6 Bristol-Myers Squibb
6.6.1 Bristol-Myers Squibb Corporation Information
6.6.2 Bristol-Myers Squibb Description and Business Overview
6.6.3 Bristol-Myers Squibb PD-1 Antibody Drug Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Bristol-Myers Squibb PD-1 Antibody Drug Product Portfolio
6.6.5 Bristol-Myers Squibb Recent Developments/Updates
6.7 Merck
6.6.1 Merck Corporation Information
6.6.2 Merck Description and Business Overview
6.6.3 Merck PD-1 Antibody Drug Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Merck PD-1 Antibody Drug Product Portfolio
6.7.5 Merck Recent Developments/Updates
6.8 Ono Pharmaceutical Co., Ltd
6.8.1 Ono Pharmaceutical Co., Ltd Corporation Information
6.8.2 Ono Pharmaceutical Co., Ltd Description and Business Overview
6.8.3 Ono Pharmaceutical Co., Ltd PD-1 Antibody Drug Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Ono Pharmaceutical Co., Ltd PD-1 Antibody Drug Product Portfolio
6.8.5 Ono Pharmaceutical Co., Ltd Recent Developments/Updates
6.9 Eli Lilly
6.9.1 Eli Lilly Corporation Information
6.9.2 Eli Lilly Description and Business Overview
6.9.3 Eli Lilly PD-1 Antibody Drug Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Eli Lilly PD-1 Antibody Drug Product Portfolio
6.9.5 Eli Lilly Recent Developments/Updates
6.10 Chugai Pharmaceutical Co., Ltd
6.10.1 Chugai Pharmaceutical Co., Ltd Corporation Information
6.10.2 Chugai Pharmaceutical Co., Ltd Description and Business Overview
6.10.3 Chugai Pharmaceutical Co., Ltd PD-1 Antibody Drug Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Chugai Pharmaceutical Co., Ltd PD-1 Antibody Drug Product Portfolio
6.10.5 Chugai Pharmaceutical Co., Ltd Recent Developments/Updates
6.11 BeiGene
6.11.1 BeiGene Corporation Information
6.11.2 BeiGene PD-1 Antibody Drug Description and Business Overview
6.11.3 BeiGene PD-1 Antibody Drug Sales, Revenue and Gross Margin (2018-2023)
6.11.4 BeiGene PD-1 Antibody Drug Product Portfolio
6.11.5 BeiGene Recent Developments/Updates
6.12 AbbVie
6.12.1 AbbVie Corporation Information
6.12.2 AbbVie PD-1 Antibody Drug Description and Business Overview
6.12.3 AbbVie PD-1 Antibody Drug Sales, Revenue and Gross Margin (2018-2023)
6.12.4 AbbVie PD-1 Antibody Drug Product Portfolio
6.12.5 AbbVie Recent Developments/Updates
6.13 TG Therapeutics, Inc
6.13.1 TG Therapeutics, Inc Corporation Information
6.13.2 TG Therapeutics, Inc PD-1 Antibody Drug Description and Business Overview
6.13.3 TG Therapeutics, Inc PD-1 Antibody Drug Sales, Revenue and Gross Margin (2018-2023)
6.13.4 TG Therapeutics, Inc PD-1 Antibody Drug Product Portfolio
6.13.5 TG Therapeutics, Inc Recent Developments/Updates
6.14 Beijing Yiqiao Shenzhou Technology Co., Ltd.
6.14.1 Beijing Yiqiao Shenzhou Technology Co., Ltd. Corporation Information
6.14.2 Beijing Yiqiao Shenzhou Technology Co., Ltd. PD-1 Antibody Drug Description and Business Overview
6.14.3 Beijing Yiqiao Shenzhou Technology Co., Ltd. PD-1 Antibody Drug Sales, Revenue and Gross Margin (2018-2023)
6.14.4 Beijing Yiqiao Shenzhou Technology Co., Ltd. PD-1 Antibody Drug Product Portfolio
6.14.5 Beijing Yiqiao Shenzhou Technology Co., Ltd. Recent Developments/Updates
6.15 3SBio
6.15.1 3SBio Corporation Information
6.15.2 3SBio PD-1 Antibody Drug Description and Business Overview
6.15.3 3SBio PD-1 Antibody Drug Sales, Revenue and Gross Margin (2018-2023)
6.15.4 3SBio PD-1 Antibody Drug Product Portfolio
6.15.5 3SBio Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 PD-1 Antibody Drug Industry Chain Analysis
7.2 PD-1 Antibody Drug Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 PD-1 Antibody Drug Production Mode & Process
7.4 PD-1 Antibody Drug Sales and Marketing
7.4.1 PD-1 Antibody Drug Sales Channels
7.4.2 PD-1 Antibody Drug Distributors
7.5 PD-1 Antibody Drug Customers
8 PD-1 Antibody Drug Market Dynamics
8.1 PD-1 Antibody Drug Industry Trends
8.2 PD-1 Antibody Drug Market Drivers
8.3 PD-1 Antibody Drug Market Challenges
8.4 PD-1 Antibody Drug Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock